Immunovaccine Inc.

Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax™, the company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus.

Expert Comments:

André Uddin, Mackie Research Capital (3/20/18)
"We are maintaining our Speculative Buy rating and slightly reducing our target price from $2.80 to $2.70 for Immunovaccine Inc., due to a recent equity financing. . .Biotech stocks normally trade up into important clinical catalysts (even in a volatile market). IMV is exploring the efficacy of its cancer vaccine DPX-Survivac in combination with other agents in different types of cancers – several key results should come out this year. . .The company could forge licensing deals for DPX-Survivac and DPX-RSV, respectively."

Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
read more >
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status.
read more >
Douglas Loe, Echelon Wealth Partners (1/11/18)
"We continue to maintain Immunovaccine Inc. as our clinical development stage Top Pick for 2018. The company's profile as a cancer immune therapy developer was raised previously following a peer acquisition undertaken by California-based infectious disease drug development giant Gilead as it relates to the $11.9B acquisition of cancer immune therapy developer Kite. . .while the transaction does ascribe a substantial market valuation for a peer of Immunovaccine, we argue that there are thematic overlaps in the company on that basis."

André Uddin, Mackie Research Capital (12/7/17)
"Immunovaccine Inc. announced this morning that it was advancing DPX-NEO (a cancer vaccine) into a Phase 1 trial in conjunction with UConn Health. . .DPX-NEO should diversify the company's pipeline. . .we are maintaining our Speculative Buy rating and target price of $2.80."

This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.
read more >
Douglas Loe, Echelon Wealth Partners (12/5/17)
"Immunovaccine Inc. presented more interim data from its 40-patient, Phase 1/2, recurrent ovarian cancer trial, testing its lead lipid (DepoVax)-based, water-free, survivin-containing cancer immune therapy DPX-Survivac in combination with partner Incyte's IDO1 checkpoint inhibitor, small-molecule drug epacadostat. . .[it's] still early days for DPX-Survivac Phase 1/2 oncology activities, but encouraging signals that the immune therapy works as expected in ovarian cancer are already available."

André Uddin, Mackie Research Capital (12/5/17)
"We are increasing our target price to $2.80 from $2.20 previously, as Immunovaccine Inc. reported good results of a Phase 1b study testing the combined treatment of the company's DPX-Surivivac and Incyte's IDO1 inhibitor epacadostat in advanced ovarian cancer patients. . .of the ten ovarian cancer patients who completed the treatment with DPX-Survivac plus 100 mg epacadostat, three had partial responses and four had stable diseases, yielding an impressive objective response rate of 30% and a disease control rate of 70%."

Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus.
read more >
André Uddin, Mackie Research Capital (11/21/17)
"Immunovaccines Inc. announced it is expanding its collaboration with Leidos to develop a DepoVax-based malaria vaccine candidate. We are maintaining our SPECULATIVE BUY rating and target price of $2.20. . .following the achievement of several preclinical milestones, Leidos and the U.S. Agency for International Development selected IMV's DepoVax platform as one of the preferred formulations to further develop a preventative, peptide-based malaria vaccine candidate. . .Leidos and USAID made this decision as IMV's DepoVax-formulated vaccine candidates demonstrated immune protection against the malaria parasite delivered by mosquito bites in prior studies."

More Expert Comments

Experts Following This Company

Endri Leno, Equity Analyst – National Bank of Canada
Douglas Loe, Analyst – Echelon Wealth Partners
Jason McCarthy, Analyst – Maxim Group
André Uddin – Mackie Research Capital

The information provided above is from analysts, newsletters, the company and other contributors.

Immunovaccine Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Unique Delivery Platform
Unique target (survivin) in Immuno-Oncology for T Cell activation
Multiple clinical milestones between now and the end of 2018
catalyst Calendar